EP4045048A4 - Orale formulierungen mit sitagliptin-hci-monohydrat mit verbesserten pharmazeutischen eigenschaften - Google Patents

Orale formulierungen mit sitagliptin-hci-monohydrat mit verbesserten pharmazeutischen eigenschaften Download PDF

Info

Publication number
EP4045048A4
EP4045048A4 EP19949416.2A EP19949416A EP4045048A4 EP 4045048 A4 EP4045048 A4 EP 4045048A4 EP 19949416 A EP19949416 A EP 19949416A EP 4045048 A4 EP4045048 A4 EP 4045048A4
Authority
EP
European Patent Office
Prior art keywords
sitagliptin
oral formulations
improved pharmaceutical
pharmaceutical characteristics
hci monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19949416.2A
Other languages
English (en)
French (fr)
Other versions
EP4045048A1 (de
Inventor
Ersin Yildirim
Bayram Kanik
Fatma ÖZTÜRK
Tansel AKTA
Celil ÜNLÜ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santa Farma Ilac Sanayi AS
Original Assignee
Santa Farma Ilac Sanayi AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Farma Ilac Sanayi AS filed Critical Santa Farma Ilac Sanayi AS
Publication of EP4045048A1 publication Critical patent/EP4045048A1/de
Publication of EP4045048A4 publication Critical patent/EP4045048A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19949416.2A 2019-10-14 2019-10-14 Orale formulierungen mit sitagliptin-hci-monohydrat mit verbesserten pharmazeutischen eigenschaften Pending EP4045048A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2019/050865 WO2021076066A1 (en) 2019-10-14 2019-10-14 Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics

Publications (2)

Publication Number Publication Date
EP4045048A1 EP4045048A1 (de) 2022-08-24
EP4045048A4 true EP4045048A4 (de) 2023-05-24

Family

ID=75538207

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19949416.2A Pending EP4045048A4 (de) 2019-10-14 2019-10-14 Orale formulierungen mit sitagliptin-hci-monohydrat mit verbesserten pharmazeutischen eigenschaften

Country Status (2)

Country Link
EP (1) EP4045048A4 (de)
WO (1) WO2021076066A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022074664A1 (en) * 2020-10-05 2022-04-14 V-Ensure Pharma Technologies Private Limited An immediate release composition of sitagliptin hydrochloride

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015114152A1 (en) * 2014-02-03 2015-08-06 Galenicum Health S.L. Stable pharmaceutical compositions containing sitagliptin in the form of immediate release tablets
EP2691083B1 (de) * 2011-03-29 2017-08-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische zusammensetzung von sitagliptin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
US7612072B2 (en) 2004-09-15 2009-11-03 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
GT200600008A (es) 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
CN101365432B (zh) * 2005-12-16 2011-06-22 默沙东公司 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
EP2139464A1 (de) 2007-03-15 2010-01-06 Nectid, Inc. Antidiabetische kombinationen mit einer verzögert freigesetzten biguanid-zusammensetzung und einer sofort freigesetzten dipeptidyl-peptidase-iv-hemmerzusammensetzung
EP2249643A4 (de) 2008-02-05 2013-10-09 Merck Sharp & Dohme Pharmazeutische zusammensetzungen aus einer kombination von metformin und einem dipeptidyl-peptidase-iv-hemmer
CA2716130A1 (en) 2008-03-04 2009-09-11 Nazaneen Pourkavoos Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
EP2356985A1 (de) 2010-02-10 2011-08-17 LEK Pharmaceuticals d.d. Neuartige pharmazeutische Zusammensetzungen aus einer Kombination aus Metformin und Sitagliptin
PL2578208T3 (pl) 2011-10-06 2014-10-31 Sanovel Ilac Sanayi Ve Ticaret As Stałe formulacje dawkowane inhibitora DPP-IV
WO2013110085A1 (en) 2012-01-20 2013-07-25 Handa Pharmaceuticals, Llc Oral dosage forms for delivering metformin and sitagliptin
WO2014170770A1 (en) 2013-03-28 2014-10-23 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
IN2014MU00651A (de) * 2014-02-25 2015-10-23 Cadila Healthcare Ltd
WO2016016770A1 (en) 2014-07-26 2016-02-04 Wockhardt Limited A novel modified release pharmaceutical composition of sitagliptin or pharmaceutically acceptable salt thereof
CN104771377B (zh) * 2015-04-15 2017-06-09 海南华益泰康药业有限公司 一种含有西他列汀或其药用盐的口服速释制剂的制备方法
TR201610368A2 (tr) 2016-07-26 2018-11-21 World Medicine Ilac Sanayi Ve Ticaret Anonim Sirketi Geli̇şti̇ri̇lmi̇ş çözünme hizina sahi̇p si̇tagli̇pti̇n fosfat anhi̇drus formülasyonlari

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691083B1 (de) * 2011-03-29 2017-08-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische zusammensetzung von sitagliptin
WO2015114152A1 (en) * 2014-02-03 2015-08-06 Galenicum Health S.L. Stable pharmaceutical compositions containing sitagliptin in the form of immediate release tablets

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Antidiabetic drug formulations ED - Darl Kuhn", IP.COM, IP.COM INC., WEST HENRIETTA, NY, US, 5 July 2018 (2018-07-05), XP013179268, ISSN: 1533-0001 *
See also references of WO2021076066A1 *

Also Published As

Publication number Publication date
EP4045048A1 (de) 2022-08-24
WO2021076066A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
EP4045480A4 (de) Pharmazeutische formulierungen
EP3256149A4 (de) Formulierung zur oralen verabreichung von wirkstoffen
EP3709978B8 (de) Orale pharmazeutische formulierung enthaltend bakterien
EP3781135A4 (de) Feste orale pharmazeutische zusammensetzungen mit sitagliptin
EP3500291A4 (de) Formulierung zur oralen verabreichung von wirkstoffen
IL285674A (en) Pharmaceutical formulations
IL290894A (en) pharmaceutical preparation
EP3927328A4 (de) Inhalierbares therapeutikum
EP3813822A4 (de) Feste orale pharmazeutische zusammensetzungen mit teriflunomid
IL290469A (en) Oral pharmaceutical preparation
EP3773730A4 (de) Wirkstofffreisetzungsformulierungen
EP3796915A4 (de) Orale formulierungen enthaltend rivaroxaban
EP4045048A4 (de) Orale formulierungen mit sitagliptin-hci-monohydrat mit verbesserten pharmazeutischen eigenschaften
EP4048276A4 (de) Feste pharmazeutische formulierungen mit ticagrelor
EP4007590A4 (de) Dihydrohonokiol enthaltende formulierungen
EP4058025A4 (de) Pharmazeutische zusammensetzungen mit ticagrelor
EP3946296A4 (de) Pharmazeutische formulierung mit verlängerter freisetzung
EP3873437A4 (de) Wässrige pharmazeutische formulierungen
EP3787602A4 (de) Verfahren zur herstellung von liposomalen arzneimittelformulierungen
IL291283A (en) Formulations for drug delivery
EP4017517A4 (de) Pharmazeutische formulierungen mit natriumpalmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinat und verfahren zu ihrer herstellung
EP3920909A4 (de) Pharmazeutische zusammensetzungen mit meloxicam
EP4005556A4 (de) Udenafil enthaltende pharmazeutische zusammensetzung
HUE062682T2 (hu) Ibuprofén tartalmú orális gyógyszerészeti készítmény
EP3845230A4 (de) Pharmazeutische zusammensetzung zur oralen verabreichung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031498500

Ipc: A61K0009200000

A4 Supplementary search report drawn up and despatched

Effective date: 20230425

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/155 20060101ALI20230419BHEP

Ipc: A61K 31/4985 20060101ALI20230419BHEP

Ipc: A61K 9/20 20060101AFI20230419BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231218